[go: up one dir, main page]

FR3084834B1 - NASAL INHALER FOR RESPIRATORY WELL-BEING - Google Patents

NASAL INHALER FOR RESPIRATORY WELL-BEING Download PDF

Info

Publication number
FR3084834B1
FR3084834B1 FR1870918A FR1870918A FR3084834B1 FR 3084834 B1 FR3084834 B1 FR 3084834B1 FR 1870918 A FR1870918 A FR 1870918A FR 1870918 A FR1870918 A FR 1870918A FR 3084834 B1 FR3084834 B1 FR 3084834B1
Authority
FR
France
Prior art keywords
nasal inhaler
respiratory
well
respiratory well
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1870918A
Other languages
French (fr)
Other versions
FR3084834A1 (en
Inventor
Marilyn Gentilhomme
Emmanuelle Peyny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urgo Recherche Innovation et Developpement
Original Assignee
Urgo Recherche Innovation et Developpement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urgo Recherche Innovation et Developpement filed Critical Urgo Recherche Innovation et Developpement
Priority to FR1870918A priority Critical patent/FR3084834B1/en
Priority to PCT/EP2019/070968 priority patent/WO2020030566A1/en
Publication of FR3084834A1 publication Critical patent/FR3084834A1/en
Application granted granted Critical
Publication of FR3084834B1 publication Critical patent/FR3084834B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a pour objet un inhalateur nasal comprenant à titre de substances actives, au moins du camphre et de l'eucalyptus ou un composé bioéquivalent de ces derniers pour aider à soulager les symptômes liés aux infections inhalateur nasal tel que précédemment défini pour le traitement des symptômes liés aux infections des voies respiratoires supérieures.The present invention relates to a nasal inhaler comprising, as active substances, at least camphor and eucalyptus or a bioequivalent compound of the latter to help relieve the symptoms associated with infections nasal inhaler as previously defined for the treatment symptoms related to upper respiratory tract infections.

FR1870918A 2018-08-10 2018-08-10 NASAL INHALER FOR RESPIRATORY WELL-BEING Active FR3084834B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1870918A FR3084834B1 (en) 2018-08-10 2018-08-10 NASAL INHALER FOR RESPIRATORY WELL-BEING
PCT/EP2019/070968 WO2020030566A1 (en) 2018-08-10 2019-08-05 Nasal inhaler for treating the symptoms associated with upper respiratory tract infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1870918A FR3084834B1 (en) 2018-08-10 2018-08-10 NASAL INHALER FOR RESPIRATORY WELL-BEING

Publications (2)

Publication Number Publication Date
FR3084834A1 FR3084834A1 (en) 2020-02-14
FR3084834B1 true FR3084834B1 (en) 2021-09-03

Family

ID=65244347

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1870918A Active FR3084834B1 (en) 2018-08-10 2018-08-10 NASAL INHALER FOR RESPIRATORY WELL-BEING

Country Status (2)

Country Link
FR (1) FR3084834B1 (en)
WO (1) WO2020030566A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1030554B1 (en) * 2022-05-23 2023-12-18 Laboratoire Puressentiel S A Sinus express respiratory tablet.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066644A1 (en) * 2006-11-02 2008-06-05 Riolan Technologies, Inc. Methods of treating epiphora

Also Published As

Publication number Publication date
WO2020030566A1 (en) 2020-02-13
FR3084834A1 (en) 2020-02-14

Similar Documents

Publication Publication Date Title
MX2023001299A (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF.
MX2016004316A (en) Dry powder inhaler.
MX2022011111A (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury.
MA43817B1 (en) Methods of treating depression using orexin-2 receptor antagonists
WO2007106617A3 (en) Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
MA37317A1 (en) Antibody formulation il-17
EP3692171A4 (en) USE OF ANTIBODIES DIRECTED AGAINST A 19-SEQUENCE-LIKE FAMILY, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
BR112021022503A2 (en) Anti-cd38 Antibody Administration Methods to Treat Multiple Myeloma
AR119159A1 (en) ANGIOEDEMA TREATMENTS
CY1110369T1 (en) NEW COOPERATIVE COMBINATION THAT INCLUDES Roflumilast And Formoterol
FR3084834B1 (en) NASAL INHALER FOR RESPIRATORY WELL-BEING
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS
MX2022013722A (en) Cysteamine for the treatment of sars-cov-2 infection.
EA202191124A1 (en) DOSAGE FORM FOR TREATMENT AND PREVENTION OF INFLUENZA AND ARVI
EA202191063A1 (en) NEW DOSE FORM
MX2018013475A (en) Carboxylic acid for treating/preventing nasal congestion.
WO2021013904A8 (en) Antibody against the oprf protein of pseudomonas aeruginosa, use thereof as a medicament and pharmaceutical composition containing same
MX2019003720A (en) COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S EVIL AND PARKINSON'S DISEASE.
FR3125704B1 (en) Combination product to relieve symptoms of sore throats
WO2004050120A3 (en) Treatment of prion-induced diseases by administration fo anti-prion antibodies
FR3127690B1 (en) Combination product to relieve sore throats
MX2020012486A (en) Composition of concentrated human immunoglobulins.
FR3094638B1 (en) Product for the prevention and treatment of motion sickness
Bovornkitti To Become The International Journal
MY183659A (en) Eurycoma longifolia extract as a nephroprotection agent

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200214

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7